Novavax to Participate in National Vaccine Advisory Committee Meeting

Rhea-AI Summary

Novavax, a biotechnology company, announced that Gregory M. Glenn, M.D., its President of Research and Development, will participate in a session at the National Vaccine Advisory Committee meeting on June 17, 2021. The discussion will focus on Novavax' COVID-19 vaccine candidate, NVX-CoV2373. The session is scheduled from 3:15 p.m. to 4:15 p.m. ET, titled Experiences in the Field: COVID-19 Vaccine Authorization and Beyond. Novavax is advancing its vaccine to combat SARS-CoV-2, aiming to enhance global health through innovative vaccines.

GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC) meeting, taking place virtually on June 17. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Session details are as follows:
Date:	Thursday, June 17, 2021
Time:	3:15 p.m. – 4:15 p.m. Eastern Time (ET)
Title:	Experiences in the Field: COVID-19 Vaccine Authorization and Beyond
Novavax Participant:	Gregory M. Glenn, M.D., President, Research and Development

For more information or to register for the meeting, visit: https://www.hhs.gov/webforms/nvac/index.html.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com 

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com 

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-national-vaccine-advisory-committee-meeting-301314763.html

SOURCE Novavax, Inc.

FAQ

What is the significance of Novavax' participation in the NVAC meeting on June 17, 2021?

Novavax will discuss its COVID-19 vaccine candidate, NVX-CoV2373, highlighting its development and potential impact.

Who is speaking on behalf of Novavax at the NVAC meeting?

Gregory M. Glenn, M.D., President of Research and Development, will represent Novavax.

What time is the Novavax session during the NVAC meeting?

The session is scheduled for June 17, 2021, from 3:15 p.m. to 4:15 p.m. Eastern Time.

What is the title of the session that Novavax will participate in?

The session is titled 'Experiences in the Field: COVID-19 Vaccine Authorization and Beyond.'

What does Novavax aim to achieve with its vaccine NVX-CoV2373?

Novavax aims to enhance global health by providing an effective vaccine against COVID-19.